Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #2811003

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities	32 558 EUR	—	—	19 155 EUR	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	150,000 EUR	—	—	— EUR	—
Purchase of property, plant and equipment, classified as investing activities	351,000 EUR	—	—	535,000 EUR	—
Purchase of intangible assets, classified as investing activities	2 000 EUR	—	—	587,000 EUR	—
Proceeds from sales of other long-term assets, classified as investing activities	66,000 EUR	—	—	— EUR	—
Purchase of other long-term assets, classified as investing activities	3,000 EUR	—	—	1,000 EUR	—
Interest received, classified as investing activities	— EUR	—	—	— EUR	—
Cash flows from (used in) investing activities	20 631 EUR	—	—	1 877 EUR	—
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities	— EUR	—	—	— EUR	—
Interest paid, classified as financing activities	— EUR	—	—	— EUR	—
Cash flows from (used in) financing activities	1 966 EUR	—	—	1 828 EUR	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	274,000 EUR	—	—	428,000 EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	13 619 EUR	—	—	19 532 EUR	—
Cash and cash equivalents	—	70 605 EUR	84 225 EUR	—	103 756 EUR